0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Glypican 3

Glypican 3

Brief Information

Name:Glypican-3
Target Synonym:OCI-5,SGBS1,DGSX,SGBS,SDYS,SGB,MXR7,OCI5,GPC3,Glypican-3,Glypican 3,Glypican Proteoglycan 3,GTR2-2,Secreted Glypican-3,Intestinal protein OCI-5,Heparan Sulphate Proteoglycan
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

GP3-HF2H1-Cell-based assay
Evaluation of CAR expression

293 cells were transfected with anti-GPC3-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1, 3 µg/ml) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-GPC3-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HF2H1) (QC tested).

GP3-H52H4-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-human GPC3 MAb (chimeric mouse-human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Glypican 3, His Tag (Cat. No. GP3-H52H4) with an affinity constant of 1.33 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

GP3-H5223-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human GPC3 MAb (chimeric mouse-human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Glypican 3 (S359F), His Tag, low endotoxin (Cat. No. GP3-H5223) with an affinity constant of 1.96 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

GPC3,OCI5,Glypican-3,GTR2-2,MXR7,DGSX,SDYS ,SGB,SGBS,SGBS1

Background

Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Yongren Medical Innovation/Guangdong Zhaotai InVivo Biomedicine) Phase 1 Clinical Hunan Zhaotai Medical Group Liver Neoplasms; Lung Neoplasms Details
GPC-3298306 GPC-3298306 Phase 2 Clinical National Cancer Center Of Japan Ovarian Neoplasms; Carcinoma, Hepatocellular Details
Anti-GPC3 CAR T-cell therapy (Nanjing University) Phase 1 Clinical Nanjing University Carcinoma, Hepatocellular Details
GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) Phase 1 Clinical Second Affiliated Hospital Of Guangzhou Medical University Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
GLYCAR T cell therapy (Baylor College of Medicine) GLYCAR Phase 1 Clinical Baylor College Of Medicine Carcinoma, Hepatocellular Details
MDX-1414 MDX-1414 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
Anti-GPC3 chimeric antigen receptor T cell therapy (Shanghai Genechem) Phase 2 Clinical Shanghai Genechem Co Ltd Liver Neoplasms; Carcinoma, Hepatocellular Details
Codrituzumab GC-33; RG-7686; RO-5137382 Phase 2 Clinical Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd Carcinoma, Hepatocellular Details
B010-A B010-A Clinical Shanghai Pharmaceuticals Holding Co Ltd Carcinoma, Hepatocellular Details
GPC3-CAR-T cell therapy CSG-GPC-3; KJgpc3-001; CAR-GPC3 T-cell; anti-GPC-3 CAR T; GPC3-CAR/CSG-GPC3 Phase 1 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
Ori-CAR-001 Ori-CAR-001 Clinical Carcinoma, Hepatocellular Details
ECT-204 ECT-204; JWATM-204 Phase 2 Clinical Liver Neoplasms; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop